Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ASC 930

Next Previous
X
Search
Drug Profile

ASC 930

Alternative Names: ASC-930; Decidua stromal cell-based therapy

Latest Information Update: 26 Jul 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ASC Therapeutics
  • Class Gene therapies; Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Graft-versus-host disease
  • New Molecular Entity No

Highest Development Phases

  • No development reported Graft-versus-host disease

Most Recent Events

  • 26 Jul 2022 No development reported - Phase-II for Graft-versus-host disease in USA (IV)
  • 23 May 2021 ASC 930 receives Orphan Drug status for Graft-versus-host disease in USA
  • 17 May 2021 ASC Therapeutics plans a phase II trial for Graft-versus-host disease (Treatment experienced) in September 2021 (IV) in the September 2021 (NCT04883918)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top